News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

UNOS Seeks New CEO to Be Voice for Diverse Needs of Donation and Transplant Community

United Network for Organ Sharing

United Network for Organ Sharing (UNOS) is conducting a national search for a permanent Chief Executive Officer. UNOS is the engine that powers the nation’s organ donation and transplant system under contract with the federal government. UNOS is seeking their next CEO, who will work collaboratively with the donation and transplant community, federal partners, Congress, and others to pursue projects and initiatives that build on ongoing successes while confronting the challenges facing the nation’s organ donation and transplant system. This includes leading the organization into a future, focusing on patient engagement, equity, innovation and driving increases in lifesaving transplants. The national search process is being conducted by a search committee at the direction of the UNOS Board of Directors and facilitated by Spencer Stuart, a global leader in executive searches with decades of experience. The Health Resources and Services Administration (HRSA) has also been involved in the process and will continue to provide feedback, as will members of the wider donation and transplant community. “We are committed to ensuring that all players in the system – patients, professionals and everyone else involved in our lifesaving mission – are represented in this process,” said Jerry McCauley, M.D., the President of the UNOS Board and the head of the candidate search committee. “We want to make sure that we’re inviting voices from different communities, experiences, and perspectives, and substantively incorporating that feedback into our process.” Maureen McBride, Ph.D. is currently serving as Interim CEO of UNOS and remains committed to focusing on continued system-wide advancement, including patient engagement and empowerment; advocating for holistic, evidence-based, patient-centered policy solutions at the federal level; and maximizing opportunities to better support research into equitable access to care. UNOS sought anonymous feedback from nearly 100 individuals to develop a representative candidate profile. These individuals are all actively engaged in the donation and transplant community, have experience in governance roles and have relevant knowledge of current issues and challenges facing the national system. These individuals also represented a broad spectrum of the donation and transplant community, covering an array of expertise, areas of involvement, backgrounds and perspectives and included patients, physicians, professionals, advocates and others. UNOS looks forward to completing the process and announcing the new CEO in the spring of 2023. “We have welcomed and will continue to welcome any and all ideas and feedback from members of the donation and transplant system,” McCauley said. “This inclusive process will result in a chosen candidate who is eager to lead a national organization of more than 400 employees, successfully compete for the next OPTN contract, convene the community, collaborate with partners at all levels and reach across barriers to drive continuous improvement.” About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

November 09, 2022 03:24 PM Eastern Standard Time

Article thumbnail Digital Asset Direct

Poolbeg Pharma makes virus "breakthrough" using AI drug discovery technology

Poolbeg Pharma PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 09, 2022 08:51 AM Eastern Standard Time

Video
Article thumbnail News Release

As More Governments Continue to Legalize Cannabis, Suitable 420 Properties Continue to Grow

Benzinga

U.S. cannabis sales in 2021 topped $25 billion and are forecasted to reach $33 billion by the end of 2022. The industry’s rapid expansion has increased demand for buying and leasing cannabis properties. Finding suitable retail space is an issue many cannabis business owners face. 420 Property has made the search more convenient by listing cannabis real estate and businesses available to buy or rent. This property management company connects you with financial institutions to fund your business and professionals to help you with zoning and making the right investment decisions. Navigating Zoning Requirements for Cannabis Properties Zoning laws regulate land uses, enforcing certain restrictions on the property. Although your state’s law permits cannabis sales, a locality has specific zoning requirements. Each municipality enforces restrictions on properties, such as enabling cannabis businesses to operate only on specific streets, determining how and where the business can be advertised and prohibiting the business from being located within 1,000 feet of a school. The numerous limitations placed on cannabis business owners make it difficult for them to set up operations. Navigating local zoning requirements and finding the ideal site for your business is best achieved by working with a property management company. Getting into the Cannabis Industry the Right Way Setting up a cannabis business is a long-term investment that requires you to choose the best method of acquiring real estate. That helps you budget and increases your chances of success. Cannabis Real Estate for Sale Buying cannabis real estate requires you to find a green-zoned property. The ideal way to finance it is with cash. Some banks are allowed to issue loans to cannabis businesses, but they’re accompanied by high fees and interest rates. Investors can choose from several premium cannabis real estate listings in California, New Jersey, Illinois, Oregon, Washington and Michigan. If those listings aren’t suitable, more are available on 420 Property. Cannabis Real Estate for Lease One of the benefits of leasing a property for your cannabis business is that you’re not concerned about the market tanking and decreasing the value of your property. Leasing retail space also requires you to have less upfront capital than buying real estate. Exiting an unsuccessful venture is more viable if you rent rather than own the property. But a major challenge entrepreneurs in the cannabis industry face is high rent. Fortunately, it’s possible to find affordable cannabis retail space to rent. You can visit 420 Property ’s website for a larger selection of real estate to lease. Cannabis Businesses for Sale Setting up a cannabis company from scratch and acquiring all the licenses, equipment and establishing a client base can be an arduous and lengthy process. You can circumvent those challenges by buying an existing cannabis business. Choose a cannabis business for sale or check out 420 Property to connect with a broker who will help you find a great offer. Cannabis Investment Opportunities Instead of setting up a business and being involved in the operations, you can profit from the cannabis industry as an investor and earn passive income. Select the best cannabis investment opportunity and let your money work for you. 420 Property lists numerous investment options for you to explore. Cannabis Real Estate Has Massive Growth Potential Considering that some experts predict the cannabis industry will reach $70 billion in annual sales by 2030, demand for cannabis real estate is rising. You require the assistance of a property management company that will provide guidance about zoning requirements and assist in finding real estate that suits your needs. You can find cannabis listings, financing, insurance, and cannabis real estate brokers on 420 property Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 08, 2022 04:25 PM Eastern Standard Time

Article thumbnail Digital Asset Direct

Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden

Unicycive Therapeautics, Inc.

Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/

November 08, 2022 09:00 AM Eastern Standard Time

Video
Article thumbnail News Release

First-of-its-kind global study finds the pandemic widely increased public scrutiny, but not understanding, of scientific research

Elsevier

New ‘Confidence in research: researchers in the spotlight’ report by Economist Impact, supported by Elsevier, reveals researchers’ outlook on global research landscape and concerns around misinformation, online abuse and widening of inequalities. Researchers are concerned about the challenges of greater public interest in scientific research, but the majority believe it has never been more important for them to engage in debate and help counter false information. The landmark ‘Confidence in research: researchers in the spotlight’ report published today finds that nearly two thirds of scientific researchers surveyed (63%) feel the pandemic has increased public attention on research. But only 38% think that better public understanding of research will be a legacy of the pandemic. (i) Conducted by Economist Impact and supported by Elsevier, a global leader in scientific publishing and information analytics, the report combines the findings from a global survey of over 3,000 scientists, scholars and researchers on how the pandemic has affected the practice of undertaking and communicating research in the face of increased public scrutiny. The full report includes recommendations for potential solutions from a Global Expert Panel of researchers, academic leaders, science organisations and policy makers. Being published in a peer-reviewed journal is the most important marker of reliability according to 74% of researchers surveyed. The study also reveals that more than half of researchers (52%) feel the pandemic increased the importance of publishing research early, prior to peer review, and many – particularly women, early career researchers and those in Global South countries – feel the pandemic has widened inequalities in, and access to, funding in their fields. More than half of respondents expressed concern about the challenges of over-simplification(52%) and the politicisation of research (56%) because of increased public attention and social media focus on research and the research process. As a result, many say they now lack confidence in their ability to communicate their findings to the public in this new environment. Fewer than one in five researchers (18%) participating in the study feel highly confident in communicating their findings on social media. This is against a background of nearly a third (32%) of respondents having experienced, or knowing a close colleague who has experienced abuse after posting research online. Half of all researchers surveyed (51%) say they feel a responsibility to engage in debate online and over two thirds (69%) believe the pandemic has increased the importance of separating quality research from misinformation. In fact, misinformation has become such a concern globally in recent years that nearly a quarter of academics (23%) now see publicly countering it as one of their primary roles in society, compared to just 16% who said this was the case before the pandemic. Alongside supporting the landmark survey by Economist Impact, Elsevier partnered with leading science and research organisations (ii) to bring together world-renowned experts, academic leaders and early career researchers to explore the impact of the pandemic on researchers and to identify potential areas of action to help the research community and enhance confidence in research. Economist Impact has combined the findings from the global survey with the insights from the extensive stakeholder dialogue to develop recommendations, which are set out in the ‘Confidence in research: researchers in the spotlight’ report published today. These include: Providing formal communications training to give researchers the tools and guidance to communicate ethically, effectively and with confidence, and incentivising strong communication skills as part of career development; Providing support for researchers in the face of online abuse by drafting clear codes of conduct and guidance on how to manage online interaction; Embedding the right incentive and reward structures to ensure that researchers’ contribution to furthering confidence in science receives appropriate recognition, in particular their role in teaching, public engagement and participation in the peer review process; Promoting collaboration and impact by providing financial incentives for researchers to collaborate in larger teams and facilitate quality trials and studies over quantity; Prioritising equity and diversity by directing research funding to countries and research communities that need it most; Adopting more digestible summaries and user-friendly formats to make it easier for policymakers, journalists or the general public to better understand and identify quality research; Prioritising consistency in R&D spending to ensure that researchers can properly plan their research, staffing and infrastructure needs. Laura Hassink, Managing Director of Scientific, Technical and Medical Journals at Elsevier, said: “The pandemic showed just how important quality research is for addressing global challenges and accelerating progress for society. Science is advancing at an extraordinary pace but that has brought new pressures on researchers such as tackling damaging misinformation, handling public scrutiny, and communicating their work with confidence. The Economist Impact report can be a helpful stimulus as all stakeholders in research come together to turn recommendations into action. At Elsevier, we are committed to supporting the research community to tackle these challenges and thank our expert partners and the thousands of academic leaders, scientists and researchers who lent their invaluable perspectives to this important collaboration.” Tracey Brown, Director, Sense about Science, and chair of a Global Expert Panel that discussed the findings said: “People who use research evidence need to know what weight they can put on it, and the pandemic exploded the numbers of people who use research evidence by millions. Researchers had to bring decision makers, the public and reporters in on all those questions about how reliable a study is, and how convincing its findings are. And they did this – they did it incredibly well the world over, with innovation and determination, but at some price. This research is a step to figuring out how to take the benefits forward, and address the challenges that make it unnecessarily difficult to talk about what we know and how.” Jonathan Birdwell, Regional Head of Policy Research & Insights for EMEA, Economist Impact said: “The pandemic demonstrated the research community’s ability to come together and solve global problems. It increased public attention on that community like never before, presenting opportunities for open science and policy influence, but also challenges around higher volume, speed and demand for simple stories. But do researchers have confidence to embrace a more public-facing role? And are their support structures and incentives fit-for-purpose amidst this new landscape? Our research finds that many researchers want to solve societal problems, influence policy and boost public understanding of research. But to do so confidently, they need more time to devote to communication, support in the face of online abuse and recognition of their public-facing contributions.” Notes to editors Statistical references / methodology (i) Economist Impact’s research was conducted with 3,144 active researchers globally between May and August 2022, spanning 100 countries and dozens of fields of expertise. (N.B. active is defined as having published an article within the last three years). This quantitative research was informed by a literature review and supplemented with qualitative in-depth interviews with a range of independent research experts, plus a Global Advisory Board. (ii) In addition to the quantitative survey and expert interviews, insights were also gathered from six regional roundtables led by Elsevier’s regional convening partners: Chinese Association for Science of Science and Science & Technology Policy (China) Japanese Association for the of Advancement Science (Japan) Koninklijke Hollandsche Maatschappij der Wetenschappen, (Netherlands) Körber Stiftung (Germany) Research!America (United States) Sense about Science (UK) Combined, these roundtables featured the perspectives of around 200 researchers covering approximately 14 countries. (iii) The survey findings, insights from the qualitative in-depth interviews and the regional roundtables were discussed by a Global Expert Panel, convened by Elsevier, which contributed recommendations for action and further exploration. These were collated by the Economist Impact and set out in the full report. More information on the methodology of the study and a full list of the experts consulted can be viewed via the report. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ journals, including The Lancet and Cell; our 43,000+ eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com About Economist Impact Economist Impact combines the rigour of a think-tank with the creativity of a media brand to engage a globally influential audience. We believe that evidence-based insights can open debate, broaden perspectives and catalyse progress across three core areas of expertise and leadership including sustainability, new globalisation and health. The services offered by Economist Impact previously existed within The Economist Group as separate entities, including EIU Thought Leadership, EIU Public Policy, Economist Events and SignalNoise. Our track record spans 75 years across 205 countries. Along with creative storytelling, events expertise, design-thinking solutions and market-leading media products, we produce framework design, benchmarking, economic and social impact analysis, forecasting and scenario modelling, making Economist Impact's offering unique in the marketplace. Visit www.economistimpact.com for more information. About Sense about Science Sense about Science is an independent non-profit that promotes the public interest in sound science and evidence. It produced the first public guide to peer review, ‘I Don’t Know What to Believe’ over a decade ago, and has since produced the first international guide to data science, co-created with user groups around the world. With its AllTrials campaign, with patients, doctors and researchers, it has achieved major changes in international regulation and compliance on the publication of clinical trial results. Sense about Science chaired the Global Expert Panel, to develop plans for improving scientific practices and helping researchers and the public to navigate research outputs. It represents UK-based stakeholders as the local Regional Convening Partner, to draw people into a discussion of what actions and interventions researchers, scholarly publishers, universities, funders and others can make to improve confidence in research in the UK. Media contacts Andrea White Elsevier Global Communications +44 7876 397206 a.white@elsevier.com Dan DiPietro-James Global Media Relations Director +1 773-251-8744 dan.james@elsevier.com Esra Erkal EVP Global Communications +44 7500 992819 e.erkal@elsevier.com Claudine Cornelis Economist Impact claudinecornelis@economist.com Harry Saunders Teneo +44 7901 313198 Harry.Saunders@teneo.com Contact Details Dan DiPietro-James dan.james@elsevier.com Company Website https://www.elsevier.com/

November 07, 2022 07:01 PM Eastern Standard Time

Article thumbnail News Release

What Does Sunshine Biopharma’s Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?

Sunshine Biopharma Inc.

The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them. Apart from name difference, generic drugs work the same as an already marketed brand-name drug in dosage form, safety, strength, administration, quality, performance characteristics and intended use. Generic drug manufacturers can apply to the U.S. Food and Drug Administration (FDA) for permission to produce drugs when a patent expires. Generic drugs typically cost 80% to 85% less than branded drugs. If you look at your medications, chances are you will find one or more generic drugs such as ibuprofen, famotidine, metformin, metoprolol and amphetamine salt combo. Growing Global Generic Drugs Market The popularity, need for and use of these drugs are fueling the growth of the global generic drug market, which is expected to grow at a compound annual growth rate (CAGR) of 7.24% from 2022 to 2027. The market is expected to be worth $311.8 billion this year and $442.3 billion by 2027. Companies like Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Viatris Inc. (NASDAQ: VTRS) and Sunshine Biopharma Inc. (NASDAQ: SBFM) are researching, running trials and releasing products to meet demand. Strategic Acquisition By Sunshine Biopharma As the market continues to grow, strategic acquisitions like Sunshine Biopharma ’s recent purchase of Nora Pharma Inc. could help shape the future of the generic drugs market. Nora Pharma is now a wholly owned subsidiary of Sunshine after the acquisition of its outstanding shares. The purchase price of approximately $21.9 million was paid by cash, Sunshine Biopharma common stock, and an earn-out amount. Nora Pharma is one of North America’s fastest-growing generic pharmaceutical companies, according to the news release issued Oct. 20. This acquisition allows Sunshine Biopharma to expand its operations into generic prescription drugs and biosimilars. “The strategic acquisition of Nora Pharma significantly expands our revenue stream and is expected to generate multiyear top-line and bottom-line growth going forward,” Sunshine Biopharma CEO Steve Slilaty said. “This acquisition gives Sunshine a solid position in the generic prescription drugs industry and brings us closer to our objective of becoming a fully integrated pharma company.” Nora Pharma Founder and President said Sunshine will provide additional expertise that will help Nora with its accelerated growth plan to provide high-quality, affordable medicines to the Canadian market. Nora Pharma has 36 employees working at its 15,000-square-foot Health Canada-certified facility and offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma and its service arm, which commercializes under the name Lea Solutions, will continue to operate without changes. “Nora Pharma will operate as a subsidiary of Sunshine Biopharma, with Mr. Chamoun as president,” Slilaty said. “We are happy to have the Nora employees join the Sunshine Biopharma family.” About Sunshine Biopharma Sunshine Biopharma (NASDAQ: SBFM) is a fully integrated pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. In addition to working with the University of Arizona to develop a treatment for COVID-19, the company also develops Adva-27a, a unique anti-cancer compound. Sunshine Biopharma reports that tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying multidrug-resistant cancer cells, including pancreatic, small-cell lung, breast and uterine sarcoma cancer cells. Clinical trials for pancreatic cancer indication will be conducted at McGill University’s Jewish General Hospital in Montreal, Canada, the company said. Sunshine Biopharma is also engaged in developing a novel anti-cancer mRNA called K1.1. The company says the data collected to date has shown that K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug-resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3) and pancreatic cancer cells (SUIT-2). Studies using nontransformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects. K1.1 mRNA is readily adaptable for delivery to patients using the proven mRNA vaccine technology. Learn more about the company here. In addition to working with the University of Arizona on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a novel anticancer mRNA called K1.1. The data collected to date have shown that K1.1 mRNA is capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects. K1.1 mRNA is readily adaptable for delivery into patients using the proven mRNA vaccine technology. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 917-633-8980 investors@sunshinebiopharma.com Company Website https://sunshinebiopharma.com/

November 07, 2022 09:28 AM Eastern Standard Time

Video
Article thumbnail News Release

Cold and Flu Season 2022: How Over-the-Counter Remedies Can Help

YourUpdateTV

Flu season has almost always been a predictable part of every winter, but the COVID-19 pandemic threw things out of whack. The 2020-2021 flu season was practically non-existent due to COVID-19 precautions and lockdowns, and last year’s flu season was definitely mild compared to pre-pandemic years. Recently, Best-Selling Author and Medical Contributor Dr. Ian Smith teamed up with Mucinex on a nationwide satellite media tour to discuss the upcoming cold and flu season and some resources that can help. A video accompanying this announcement is available at: https://youtu.be/c4AY6pLO1kU Many health experts are predicting the 2022-2023 flu season will be a severe one, due to several factors. The main reason the flu basically disappeared the last two years was the behavior changes people made to avoid COVID – staying home, avoiding public gatherings, wearing masks, and not traveling. That also prevented the flu virus from spreading like usual. Those measures have been mostly abandoned – in addition, without the last two ‘flu seasons’ many individuals’ immunity to seasonal flu will be decreased. It is possible that we could see a higher rate of severe illness due to the flu this year. Many experts have looked to Australia, where flu season runs from April to September. They are just coming out their most devastating flu season in five years, which could be a precursor as to what we can expect to see in the U.S. The best way to prevent and limit the effects if you do contact the flu is to get vaccinated. It can take up to two weeks for the vaccine to be most effective after administration, and since the influenza virus is already circulating, it is best to do this as soon as possible. Key preventative measures like washing your hands often and covering your nose and mouth with a tissue when you cough or sneeze and sneezing into your elbow if you don’t have a tissue can be extremely effective in preventing the spread of germs. If you do find yourself with flu-like symptoms, such as cough and congestion, there are options available to help you feel better and over-the-counter remedies are the first stop. While over-the-counter remedies don’t cure the flu virus, they can go a long way towards helping treat the symptoms. Dr. Ian’s go-to is Mucinex Extended-Release Tablets, because they are clinically proven to last up to 12 hours. As the #1 pharmacist recommended expectorant, Mucinex Extended-Release Tablets relieve chest congestion and thin and loosen mucus, which can provide relief for your chest congestion, making your cough more productive. People must use over-the-counter products as directed. If symptoms persist, you should contact your healthcare professional and get checked out if deemed necessary. You can find Mucinex online at Mucinex.com or stop by Walmart or your local pharmacy retailer. About Dr Ian Smith Dr. Ian Smith is the author of the #1 New York Times bestselling books, SHRED: THE REVOLUTIONARY DIET, and SUPER SHRED: The Big Results Diet, and BLAST THE SUGAR OUT. Dr. Smith’s highly anticipated newest book, The Clean 20, became an instant New York Times best seller, helping hundreds of thousands of people reduce bad sugars from their diet, lose weight, lower blood sugar levels, and cut the cravings. Dr. Smith was appointed by President Obama to a second term on the prestigious President’s Council on Fitness, Sports, and Nutrition. He is currently the medical contributor and co-host of the nationally syndicated television show The Rachael Ray Show. He is a former co-host of the Emmy award winning syndicated daytime talk show, The Doctors. He also served as the medical/diet expert for six seasons on VH1’s highly-rated Celebrity Fit Club, and is the creator and founder of the national health initiatives The 50 Million Pound Challenge and The Makeover Mile. Dr. Smith is the former medical correspondent for NBC News network and for NewsChannel 4 in New York, where he filed reports for NBC Nightly News and The Today Show as well as WNBC’s various news broadcasts. He has appeared extensively on various broadcasts including The Oprah Winfrey Show, The View, Dr. Oz, Steve Harvey Show, The Talk, Larry King Live, Anderson Cooper 360, CNN, MSNBC and many more. He has written for various publications including Time, Newsweek, Men’s Fitness, and the New York Daily News, and has been featured in several other publications including, People, Redbook, Details Magazine, Essence, Ebony, University of Chicago Medicine on the Midway, Cosmopolitan, and Black Enterprise. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 04, 2022 10:05 AM Eastern Daylight Time

Video
Article thumbnail News Release

Willamette Valley Benefits Joins AmeriLife

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, announced today that it has partnered with Willamette Valley Benefits. Under the leadership of longtime industry veteran and CEO Elma Friend, Willamette Valley Benefits specializes in the marketing and distribution of Medicare Advantage, Medicare Supplement, and ancillary health solutions to clients throughout the Pacific Northwest and Mountain West. Per the agreement, terms of the deal were not disclosed. "This is an exciting time for women in this industry,” said Friend. “We are a women-owned and operated business and have continued to see growth. I believe in the nurturing, compassionate side of what we do and taking care of people is our priority. As a female-driven operation, we continue to see more women entering this field and it’s a great fit because AmeriLife understands that diverse, empowered and client-first agents are key to delivering the right solutions and service.” Headquartered in Portland, OR., Willamette Valley Benefits has, for more than 16 years, helped clients navigate the complexities of healthcare via a dedicated staff of Medicare and health insurance professionals. Friend, also its founder, started with HealthNet and in launching Willamette Valley Benefits, committed herself and her firm to being a service-oriented business. Today, Willamette Valley Benefits takes a supportive approach when it comes to bringing in new agents. They collaborate with them consistently on education, service, compliance and support, ensuring that each agent has what they need to build their book of business and have a better work-life balance. Willamette Valley Benefits’ growing team currently serves communities in Oregon, Washington, Arizona and Idaho, and has recently branched into Texas. Already deeply familiar with AmeriLife through its longstanding relationship with Jack Schroeder and Associates, Willamette Valley Benefits will now have full access to AmeriLife’s best-in-class technology and resources and leading distribution platform, positioning the firm for significant growth. “Willamette Valley Benefits is, without a doubt, representative of the new face of our industry,” said Mike Vietri, AmeriLife’s Chief Distribution Officer. “AmeriLife is excited to add such a diverse and performative agency to its portfolio of companies. We look forward to working with Elma and her team to grow their operations and empower more of their agents to help people live longer, healthier lives.” ### About Willamette Valley Benefits Willamette Valley Benefits, Inc. is a local independent Medicare and health insurance agency based in Milwaukie, OR. With a passion for helping clients navigate their insurance needs, they are committed to making sure the information clients receive is clear and understandable. The team collaborates directly with clients to reduce their workload, clear up confusion and be confident that there is someplace to go when their health coverage questions need to be answered. Willamette Valley Benefits has been in business for more than 16 years and has grown through word of mouth, offering its services at no cost to those who need assistance. For more information visit WVBenefits.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

November 03, 2022 01:00 PM Eastern Daylight Time

Article thumbnail News Release

Software Effective Solutions’ (OTC: SFWJ) Medcana Acquires Controlling Stake in Eko2o Environmental

Software Effective Solutions Corp.

McapMediaWire -- Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) subsidiary Medcana has acquired a controlling stake in Eko2o Environmental Solutions S.A.S. of Medellin, Antioquia. a company focused on developing infrastructure for agriculture, primarily with greenhouse construction and irrigation systems in Colombia and South America. With this acquisition, the Company is expanding its infrastructure and overall capabilities toward additional market opportunities and strategic partnerships. Juan Ricardo Velez is CEO for Eko2o and is renown in the industry for his experience and track record for success. As well, execs are confident that the engineering talent and vendor support that comes with this acquisition will set Eko20 as a market leader in Colombia and South America very quickly. Gabriel Diáz, CEO of Medcana states “This acquisition further amplifies our investments in the industry and provides expansive opportunities for growth in the industry. We are honored to be working with a team equipped with a deep understanding of, and extensive experience in greenhouse and irrigation technologies. We are building something special here and Eko2o is a very important piece of our puzzle.” Juan Ricardo Velez CEO and founder of Eco2o is a Civil Engineer from University of Medellin, served and retired as army Major in Colombian Army. He has advanced studies in Israel and Spain focusing on irrigation systems and greenhouses. His experience and his team are unrivaled in Colombia and most of South America. About Software Effective Solutions/MedCana: Software Effective Solutions/MedCana is a global infrastructure and holding company in the cannabis industry. The recent acquisition of a software company expanded the offering to provide traceability from plant to product. MedCana's initial focus is on developing clients and companies in Latin America, with an initial focus on Colombia and partnerships with laboratories, research facilities, and hospitals throughout the world. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Signed. /s/ Jose Gabriel Diaz, CEO www.medcana.net info@medcana.co FOR MORE INFORMATION PLEASE CONTACT: Chris Greta 512-587-5175 chris@chrisgreta.com www.medcana.net info@medcana.co Contact Details Chris Greta +1 512-587-5175 chris@chrisgreta.com Company Website https://www.medcana.net/

November 03, 2022 10:57 AM Eastern Daylight Time

1 ... 189190191192193 ... 303